निर्देशित दृश्य
जेनेटिक्स में नए हैं? ब्राउज़ करते समय हम हर शब्द को सरल भाषा में समझाते हैं। वही पेज, बस मदद पहले से मौजूद।
विशेषज्ञ दृष्टिकोण
आप जीव विज्ञान पहले से जानते हैं। बस सामग्री, साफ़ और संक्षिप्त, कोई अतिरिक्त स्पष्टीकरण नहीं। यह डिफ़ॉल्ट व्यू है।
CRISPR Decoded अपनी कोई खबर नहीं देता। नीचे दी गई हर headline उसके बगल में लिखे publisher की है और उनकी वेबसाइट पर नई tab में खुलती है, जहाँ उनकी शर्तें, paywalls और tracking लागू होती हैं। हम आपको भेजने से पहले पुष्टि करेंगे।
University of Missouri researchers have created rice plants that resist bacterial blight, a devastating disease that threatens one of the world's most important food crops. The advance could help farmers in parts of Asia and Africa, where the disease can destroy harvests and threaten livelihoods.
Phys.org — Molecular Biology
Scientists have long used a powerful gene-editing tool called CRISPR to make precise changes to DNA. But a different version of the technology, known as Cas13a, targets RNA, the…
CRISPR-Cas13
Phys.org — Molecular Biology
A new engineered gene-editing system, proven in bacteria and showing promise for use in plants, animals and humans, addresses some limitations of current gene-editing tools, with…
Vector production costs have a disproportionate influence on gene therapy prices, according to researchers who say that, given this, choosing the vector manufacturing method that best suits…
Gene Therapy (gene addition)Beacon Therapeutics has succeeded in a genetic eye disease where large drugmakers have failed, including Johnson & Johnson and Biogen. On Monday, Beacon said its gene therapy laru-zova for…
Retinitis Pigmentosa Gene Therapy (gene addition)A new open-access study introduces RiSpy, a data-driven fingerprinting framework that makes the identification of genome-edited (GE) rice lines more robust, scalable and broadly applicable…
Editing a plant's genes is only half the battle. Before a new, improved trait can ever reach a farmer's field, scientists must be able to grow a whole plant from just a few edited cells—a…
Two recipients of gene-edited pig kidneys have successfully received human organs, a milestone in the wider effort to advance xenografts.
Novartis and Bristol Myers Squibb have paused multiple cell therapy trials, while $480,000 has now become a routine price for a cancer drug. Read the latest pharma headlines in today's…
CancerPresident Trump’s pledge to make pricey weight loss drugs widely available for low-income Americans through Medicaid is not panning out
Gene Therapy (gene addition)Nature invented biodegradable plastic long before humans did—and animals may have been feeding on it for hundreds of millions of years. Researchers discovered that dozens of animal species…
Researchers used genome editing to block the production of red pigments in lettuce, causing other beneficial plant compounds to build up instead. The lettuce continued to grow normally…
The Canadian entrepreneur has always pushed the boundaries of gene editing, once attempting to turn horses into unicorns. Now she is set on modifying human embryos – something her…
Researchers at the Salk Institute have used CRISPR to uncover hidden microproteins that control fat cell growth and lipid storage, identifying one confirmed target, Adipocyte-smORF-1183…
पत्रकारिता नहीं: घर में लिखा गया
हमारे अपने database रिकॉर्ड से AI की सहायता से तैयार किए गए संक्षिप्त सारांश। इन्हें किसी और ने रिपोर्ट नहीं किया है, इन पर कोई byline नहीं है, और ठीक इसी कारण से इन्हें ऊपर की खबरों से अलग रखा गया है।
CRISPR Decoded organises its 92 pages across four evidence levels, and the distinction matters because it signals how much human data sits behind any claim. Laboratory research, covering 5 pages, describes work done entirely in cells or computer models. No human has received anything at this stage. Preclinical research, covering 12 pages, adds animal studies but still involves no human trials. Both levels indicate that a technology or disease application is at an exploratory stage, and according to CRISPR Decoded records, conditions such as Parkinson's disease sit at laboratory research while Duchenne muscular dystrophy remains preclinical. Clinical research is the largest category, with 59 pages. It covers every phase of human trials, from first-in-human Phase I studies through to Phase III registrational programmes. Being in clinical research means human data exists, but it does not mean a therapy is proven safe, effective or available. Approved treatment, covering 16 pages, is reserved for therapies that have cleared regulatory review. According to CRISPR Decoded records, only one gene editing therapy, Casgevy, holds that status, making the approved category the narrowest and most consequential distinction of all.
16h agoApproved gene editing treatments exist today for sickle cell disease and beta thalassemia, and the records of CRISPR Decoded point to a shared reason: both diseases involve blood stem cells that can be removed from a patient, edited outside the body, and returned. This ex vivo approach sidesteps one of the hardest problems in the field, namely delivering editing machinery reliably to cells inside a living person. Casgevy, a CRISPR-Cas9 therapy, reached approval on exactly this basis. Conditions that require editing inside the body face a steeper path. The liver is relatively accessible via lipid nanoparticles, which is why ATTR amyloidosis and hereditary angioedema have reached Phase III. Tissues such as muscle, the central nervous system and the lung are harder to reach, and Duchenne muscular dystrophy, Huntington's disease and cystic fibrosis remain preclinical in these records. A 2025 death in the MAGNITUDE liver-targeting trial also illustrated a further constraint: an irreversible in vivo edit cannot be withdrawn if something goes wrong, raising the safety threshold regulators apply.
16h agoAccording to CRISPR Decoded records, the most recent developments span 2023 to 2026 and range from a landmark approval to the first positive Phase 3 result for in vivo gene editing. In November 2023, the UK MHRA authorised Casgevy, a CRISPR-Cas9 therapy, for sickle cell disease and beta thalassemia, with FDA authorisation following in December 2023 and January 2024. This represents an approved treatment, the highest evidence level recorded. In 2025, results from PM359 in chronic granulomatous disease provided the first clinical evidence for prime editing, rated clinical research: prime-edited stem cells engrafted and restored immune function. That same year, a participant in the Phase 3 MAGNITUDE trial of nexiguran ziclumeran died following severe liver injury, prompting a voluntary pause and an FDA clinical hold. The hold on MAGNITUDE was later lifted. In 2026, Intellia reported positive Phase 3 results, clinical research evidence, for lonvoguran ziclumeran in hereditary angioedema, described in CRISPR Decoded records as the first successful registrational trial of in vivo gene editing, with a licence application signalled for later that year.
16h agoAs reflected in CRISPR Decoded records, one gene editing treatment has reached regulatory approval: Casgevy, a CRISPR-Cas9 therapy for sickle cell disease and beta thalassemia, authorised first by the UK MHRA in November 2023 and subsequently by the FDA. Two approved lentiviral gene-addition therapies, Lyfgenia and Zynteglo, address the same blood disorders but use a different mechanism and are not gene editing. Four gene editing programmes have reached Phase III. Nexiguran ziclumeran targets ATTR amyloidosis, lonvoguran ziclumeran targets hereditary angioedema and reported the first positive Phase III result for in vivo gene editing, risto-cel uses base editing for sickle cell disease, and BEAM-302 applies base editing to alpha-1 antitrypsin deficiency. Several earlier-stage trials cover cancer, familial hypercholesterolemia, chronic granulomatous disease and diabetes. A significant portion of the broader landscape remains preclinical or at discovery stage, including programmes for Duchenne muscular dystrophy, cystic fibrosis, hemophilia, Huntington's disease, Parkinson's disease and Alzheimer's disease, underlining how much of gene editing's potential has not yet been tested in humans.
16h agoहर वह publisher जिनसे CRISPR Decoded सामग्री लेता है, और अभी उनकी कितनी खबरें यहाँ मौजूद हैं।
| प्रकाशक | आलेख संग्रहीत | सबसे हाल का |
|---|---|---|
| GEN — Genetic Engineering News | 65 | Oct 27, 2026 |
| Endpoints News | 50 | Oct 27, 2026 |
| Nature Genetics | 30 | Oct 26, 2026 |
| STAT | 24 | Oct 27, 2026 |
| Phys.org — Molecular Biology | 20 | Oct 27, 2026 |
| Medical Xpress — Genetics | 15 | Oct 22, 2026 |
| Science Daily — Gene Therapy | 6 | Sep 7, 2025 |
| The Guardian — Genetics | 6 | Sep 21, 2026 |
| Science Daily — Genes | 5 | Oct 7, 2026 |
| Science Daily | 2 | Aug 17, 2026 |
| New Scientist | 2 | Sep 25, 2026 |
| FDA | 2 | Sep 17, 2026 |
| MIT Technology Review | 2 | Aug 14, 2026 |
केवल headlines, publisher के नाम और links। लेख संबंधित publishers की संपत्ति हैं। तारीखें प्रत्येक feed द्वारा बताई गई प्रकाशन तारीखें हैं, UTC में। जहाँ छवियाँ दिखाई जाती हैं, वे publisher के सर्वर से आती हैं और उन्हीं की हैं।
यह link एक ऐसी वेबसाइट खोलती है जिसे हम नहीं चलाते। हम उसकी सामग्री, उसकी सटीकता या वह आपके डेटा को कैसे संभालती है, इस पर कोई नियंत्रण नहीं रखते, जिसमें उनके अपने cookies और tracking शामिल हैं। वहाँ जो कुछ भी आप पढ़ें, उसकी हमने समीक्षा नहीं की है।